In its upcoming report, Becton Dickinson (BDX Quick QuoteBDX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $3.91 per share, reflecting an increase of 2.6% compared to the same period last year. Revenues are forecasted to be $5.91 billion, representing a year-over-year increase of 8.7%.

The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

Given this perspective, it's time to examine the average forecasts of specific Becton Dickinson metrics that are routinely monitored and predicted by Wall Street analysts.

According to the collective judgment of analysts, 'Revenues- BD Interventional' should come in at $1.35 billion. The estimate indicates a year-over-year change of +6.9%.

Analysts forecast 'Revenues- BD Interventional- Surgery' to reach $391.29 million. The estimate indicates a change of +6.3% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenues- BD Interventional- Peripheral Intervention' will likely reach $532.03 million. The estimate indicates a change of +6% from the prior-year quarter.

The consensus estimate for 'Revenues- BD Interventional- Urology and Critical Care' stands at $422.90 million. The estimate indicates a change of +8.4% from the prior-year quarter.

The average prediction of analysts places 'Revenues- BD Medical- Medication Management Solutions- International' at $206.30 million. The estimate points to a change of +5.8% from the year-ago quarter.

Analysts predict that the 'Revenues- BD Life Sciences- Biosciences- International' will reach $253.49 million. The estimate indicates a year-over-year change of +2.6%.

It is projected by analysts that the 'Revenues- BD Interventional- Peripheral Intervention- United States' will reach $283.14 million. The estimate suggests a change of +6.1% year over year.

Analysts expect 'Revenues- BD Interventional- Urology and Critical Care- United States' to come in at $331.60 million. The estimate indicates a change of +8.4% from the prior-year quarter.

The collective assessment of analysts points to an estimated 'Revenues- BD Interventional- United States' of $908.83 million. The estimate points to a change of +6.8% from the year-ago quarter.

The consensus among analysts is that 'Revenues- BD Interventional- Surgery- International' will reach $96.79 million. The estimate indicates a change of +8.8% from the prior-year quarter.

Based on the collective assessment of analysts, 'Revenues- BD Interventional- Peripheral Intervention- International' should arrive at $248.90 million. The estimate points to a change of +5.9% from the year-ago quarter.

Analysts' assessment points toward 'Revenues- BD Interventional- Urology and Critical Care- International' reaching $92.78 million. The estimate suggests a change of +10.5% year over year.

Becton Dickinson shares have witnessed a change of -7.7% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #4 (Sell), BDX is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .